YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Spruce Biosciences press release [https://seekingalpha.com/pr/20616630-spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SPRB [https://seekingalpha.com/symbol/SPRB]): Q2 GAAP EPS of -$6.68. * Cash…
American Express, Biogen upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Quick Read A U.S.-Iran ceasefire deal sent the Nasdaq surging 3% to 26,683 and the Dow to a new all-time high at 51,671, while oil plunged 4%. UBS nearly doubled Dynatrace's (DT) price target to $60, while Bank of America upgraded Exxon Mo…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Keefe Bruyette upgraded Toll Brothers(TOL)…
SOUTH SAN FRANCISCO, Calif., May 04, 2026--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significa…
Spruce Biosciences (SPRB [https://seekingalpha.com/symbol/SPRB]) has priced its public offering [https://seekingalpha.com/pr/20480051-spruce-biosciences-announces-pricing-of-public-offering-of-common-stock-and-pre-funded] of 1.15M common s…
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s transition toward its next phase of gro…
(RTTNews) - Harbour BioMed announced that, through its wholly-owned subsidiary, it has exercised its warrant to acquire common stock in Spruce Biosciences Inc. (SPRB). As a result of this transaction, Harbour BioMed now holds approximately…
Oppenheimer initiated coverage of Spruce Biosciences (SPRB) with an Outperform rating and $283 price target. Further to FDA’s confirmation that existing and what the firm views as “compelling” clinical biomarker data could drive accelerate…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy from H…
Bet_Noire / iStock via Getty Images Quick Read Stocks continued higher on Monday as the “Santa Claus” rally appears to be here. Small-caps were the big winner Monday as the Russell 2000 pushed higher again. Look for trading volume to reall…
(RTTNews) - Several biotechnology and pharmaceutical companies posted notable gains in after-hours trading on Monday, following a mix of corporate updates and upcoming event announcements. Jasper Therapeutics, Inc. (JSPR) surged 21.51% to…
Check out the companies making headlines before the bell. Trilogy Metals — U.S.-listed shares of the Canadian minerals explorer soared more than 222% after the White House said it would take a stake in the company . The Trump administratio…
[Modern Medicine Laboratory: Diverse Team of Multi-Ethnic Young Scientists Analysing Test Samples. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs, Doing Research] gorodenkoff/iStock via Getty Images *…
* Spruce Biosciences (OTC:SPRB [https://seekingalpha.com/symbol/SPRB]) will resume trading on Nasdaq, September 15, 2025. * The company focuses on developing therapies for neurological disorders with high unmet medical need. * SPRB shares…
Illumina (ILMN) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This…
SOUTH SAN FRANCISCO - Spruce Biosciences, Inc. (OTCQB:SPRB), currently trading with a market capitalization of $5.15 million, will implement a 1-for-75 reverse stock split of its common stock effective August 4, 2025, with trading on a spl…
Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impac…
SOUTH SAN FRANCISCO, Calif., June 12, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with signif…
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif., May 25, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a la…
SOUTH SAN FRANCISCO, Calif., May 24, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with signifi…
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award SOUTH SAN FRANCISCO, Calif., May 22, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focu…
While Spruce Biosciences, Inc. (NASDAQ:SPRB) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 19% in the last quarter. While that might be a setback, it doesn't ne…
CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Top…
Mitchell Geffner, M.D., to Present on May 7, 2023 from 12:30 pm – 2 pm PT SOUTH SAN FRANCISCO, Calif., May 04, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and…
SOUTH SAN FRANCISCO, Calif., May 02, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with signifi…
Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces i…
CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical…
SOUTH SAN FRANCISCO, Calif., February 28, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with si…
Let’s talk about winning in the stock market. You can make money no matter what the overall economic conditions are – whether stocks go up or down, there will be opportunities to profit by the moves. The key, of course, is understanding wh…
A South San Francisco biotech company, hoping to deliver top-line results from key drug studies targeting a genetic hormonal disorder, raised $53.6 million in a private investment in a public entity, or PIPE, deal. For Spruce Biosciences I…
SOUTH SAN FRANCISCO, Calif., February 09, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with si…
SOUTH SAN FRANCISCO, Calif., February 01, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with si…
Spruce Biosciences, Inc. (SPRB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SPRB's 50-day simple moving average broke out above its 200-day moving average; this is kno…
Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023 Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic CAH Enhances Study Design; Topline Data from Adolescents Antic…
It's been an up-and-down week for Bay Area life sciences stocks as health care executives start to flow into San Francisco for the 41st annual J.P. Morgan Healthcare Conference. Continue reading